Biomarkers /
RAD50
Overview
RAD50 homolog (RAD50) is a gene that encodes a protein that functions in double-strand break repair. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
RAD50 is altered in 1.51% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, bladder urothelial carcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in RAD50 are RAD50 Mutation (1.22%), RAD50 Nonsense (0.16%), RAD50 Loss (0.10%), RAD50 R938* (0.02%), and RAD50 V703A (0.08%) [3].
Clinical Trials
Significance of RAD50 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.